To determine the expression of the tyrosine kinases platelet-derived growth factor receptor (PDGFR) and c-Kit in vestibular schwannoma (VS) and to determine the potential role of imatinib mesylate (Gleevec) in regulating the growth and cell death of this tumor. Background: Protein tyrosine kinases are transmembrane tyrosine kinase receptors that transduce signals from inside and outside the cell and function as relay points for signaling pathways. They have a key role in numerous processes that affect cell proliferation, tumorigenesis, cancer invasion, metastasis, and modulation of apoptosis. A few of these kinases have been demonstrated to be overexpressed and dysregulated in many carcinomas, sarcomas, and benign tumors. Methods: Immunohistochemical staining was used to investigate the expression of PDGFR and c-Kit in archived acoustic neuroma tissue. Clinical data including size of tumors, age, sex, and symptoms were correlated with kinase expression, whereas Western blot analysis and immunofluorescence were performed to demonstrate the expression and localization of PDGFR and c-Kit in HEI193, an immortalized VS cell line. Clonogenic survival assays were performed to assess proliferation inhibition by Gleevec. Gleevec's effect on the cell cycle profile also was investigated via flow cytometry analysis.
Hypothesis:
To determine the expression of the tyrosine kinases platelet-derived growth factor receptor (PDGFR) and c-Kit in vestibular schwannoma (VS) and to determine the potential role of imatinib mesylate (Gleevec) in regulating the growth and cell death of this tumor. Background: Protein tyrosine kinases are transmembrane tyrosine kinase receptors that transduce signals from inside and outside the cell and function as relay points for signaling pathways. They have a key role in numerous processes that affect cell proliferation, tumorigenesis, cancer invasion, metastasis, and modulation of apoptosis. A few of these kinases have been demonstrated to be overexpressed and dysregulated in many carcinomas, sarcomas, and benign tumors. Methods: Immunohistochemical staining was used to investigate the expression of PDGFR and c-Kit in archived acoustic neuroma tissue. Clinical data including size of tumors, age, sex, and symptoms were correlated with kinase expression, whereas Western blot analysis and immunofluorescence were performed to demonstrate the expression and localization of PDGFR and c-Kit in HEI193, an immortalized VS cell line. Clonogenic survival assays were performed to assess proliferation inhibition by Gleevec. Gleevec's effect on the cell cycle profile also was investigated via flow cytometry analysis.
Results: Expression of PDGFR in the formalin-fixed VS tumor tissue was observed in 23 (67.5%) of the 34 samples. C-kit was expressed in 18 (52.9%) of the 34 samples. Western blot analysis demonstrates positive expression of c-Kit and PDGFR-Q in HEI193 and a primary VS culture. Western blot analysis showed downregulation of phospho-c-kit and phospho-PDGFR-Q with 5 and 10 uM Gleevec. Immunofluorescent staining of this cell line also reveals that PDGFR-A is localized primarily in the cytoplasm, whereas c-Kit is both nuclear and cytoplasmic. Cell cycle analysis of HEI193 96 hours after incubation with Gleevec indicates a dose-dependent increase in G1 from 61.6% to 70.7% and 74% at 5 and 10 uM of Gleevec, respectively. Colony formation assays demonstrate dose-dependent growth inhibition by Gleevec, in the HEI193 cell line as well as in a VS cell culture derived from a fresh tumor. Conclusion: The expression of PDGFR-Q and c-Kit in VS tissue may indicate novel molecular targets involved in the development of this tumor. Direct inhibition of these molecules by Gleevec may have relevant therapeutic applications. Key Words: Acoustic neuromaVc-kitVGleevecVImatinib mesylateVPlatelet-derived growth factor receptorVSTI-571V Tyrosine kinasesVVestibular schwannoma. Otol Neurotol 32:163Y170, 2011.
Vestibular schwannomas (VSs) are rare, slow-growing neoplasms that originate from the VIIIth cranial nerve sheath. The vast majority of VSs develop from the Schwann cell investment of the vestibular portion of the vestibular cranial nerve. Currently, VSs are managed in 1 of 3 ways: 1) surgical excision of the tumor, 2) stereotactic radiation therapy, or 3) careful serial observation with magnetic resonance imaging (MRI). Improvements in surgical technique and postoperative care have enabled the safe removal of VSs. However, there remains a select group of individuals with VSs for whom nonoperative management would seem desirable, such as patients with significant cardiovascular or pulmonary disease, patients with minimal symptoms, or those with a VS in their only hearing ear (1) . Furthermore, given the benign, slowgrowing nature of this tumor and the gravity of the operation, the potential for a medical treatment of VS could revolutionize its management (2) . Even if only a partial Copyright @ Otology & Neurotology, Inc. Unauthorized reproduction of this article is prohibited.
response could be achieved, avoidance of surgery in a select cohort would be a significant advancement.
The molecular biology in the development of VS is poorly understood. One category of patients who develop VSs are patients with neurofibromatosis 2 (NF2), an autosomal dominant disorder clinically characterized by bilateral VS and other intracranial and spinal tumors. The NF2 gene, located in chromosome 22q (3) , is a tumor suppressor gene that functions as a critical regulator of Schwann cell growth, with inactivation of the NF2 gene being an essential step in tumorigenesis. The transcribed messenger RNA produces a protein designated as merlin or schwannomin (4, 5) .
Merlin loss occurs in both NF2 and sporadic VSs, the second category of VSs, which accounts for most VS tumors. Loss of chromosome 22q has been demonstrated in up to 45% of sporadic VS (6) , and biallelic inactivation of the NF2 gene has been demonstrated in almost all NF2-related VSs (7) .
Aside from the NF2, there are several other genes implicated in the genesis of VS. The neuregulin gene family seems to act as schwann cell mitogens (8) . These proteins signal via the c-erb receptor family, with c-erb 2 and 3 being the main receptors associated with schwann cells (9) . Neuregulin-1/ErbB2 signaling has been implicated in the proliferation of VSs (10) . Fibroblast growth factors and their receptors also are known to have a mitogenic effect on schwann cells (11) .
Tumor expression of different cytokines and other factors that could regulate schwann cell proliferation and tumor growth have been addressed in studies of Ki-67 (4), proliferating cell nuclear antigen (12) , nerve growth factor receptor (13) , transforming growth factor receptor (14) , fibroblast growth factor (14, 15) , vascular endothelial growth factor (16, 17) , epidermal growth factor receptor (2), and interleukin 6 (18) .
In the last few years, there has been a tremendous interest in tyrosine kinases (TKs) as genes that may play a critical role in tumor development. Targeted therapy using small molecule inhibitors of these kinases has emerged as an attractive alternative to the toxic drugs used for chemotherapy. Clinical agents have been developed to inhibit several of these TKs, including EGFR, HER-2, Bcr-Abl, PDGFR, VEGF, and c-kit (19Y21).
STI571 (imatinib mesylate, Gleevec; Novartis Pharmaceuticals Corporation, NJ, USA) is an example of such a small-molecule TK inhibitor. Gleevec, a drug designed to treat chronic myelogenous leukemia (CML) by inactivating the Bcr-Abl fusion kinase also directly interferes with TKs that are aberrantly activated in tumor cells. In solid tumors, Gleevec has been shown to inhibit the growth of ovarian cancer cells through plateletderived growth factor receptor (PDGFR) inactivation (22) . Gleevec also has been demonstrated to inhibit the growth of c-KitYpositive small cell lung cancer cell lines (23, 24) , PDGFR-expressing glioblastoma cells (25) , and c-kitY positive gastrointestinal stromal tumor cell lines (26) . These data suggest that Gleevec may be therapeutically relevant for other solid tumors in which activation of the c-Kit or PDGFR pathways may be responsible for tumorigenesis (27) .
To determine if tyrosine kinases activation may have a role in the development of VS, we began by investigating the differential immunohistochemical expression profiles of the tyrosine kinases PDGFR and c-Kit in VSs. Clinical data including size of tumors, age, sex, and symptoms were correlated with kinase expression. To further investigate the role of tyrosine kinases, studies were performed using Gleevec on a virally (HPV E6/E7) immortalized human VS cell line, HEI193 (28) . Because virally transformed cells may contain genetic modifications not normally present in VS cells, primary VS cells grown in culture also were used in our experiments for purposes of comparison.
MATERIALS AND METHODS

Tissue Samples
The records of all patients with a diagnosis of VS at the Servicio de Otorrinolaringología, Hospital Donostia, San Sebastián, Spain, between January 1991 and December 2002 were reviewed. Demographic data recorded on all patients included age, sex, and symptoms. Information on physical findings, such as audiogram results and tumor size; surgical approach; morbidities; and the last clinic visit also were all tabulated and evaluated.
Immunohistochemistry
The appropriate formalin-fixed, paraffin-embedded VSs were obtained from the archives of the Pathology department in accordance with the institutional review board of Hospital Donostia, San Sebastián, Spain. Approximately 4-Km sections were cut and placed on 3-aminopropyltriethoxysilaneYcoated slides. Immunohistochemical studies were performed using rabbit polyclonal antibodies against PDGFRA and c-Kit (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Negative control slides were from the same tissue but without the addition of the primary antibodies. Formalin-fixed, paraffin-embedded head and neck squamous cell carcinoma tissues were used as positive controls, and normal VIIIth cranial nerve was assessed for baseline c-kit and PDGFR-Q staining. The samples were heated for 1 hour at 60-C, deparaffinized in xylene and rehydrated in a graded series of ethanol. Antigen retrieval was performed by steam heating with Dako target retrieval solution. The endogenous peroxidase was quenched by 3% H 2 O 2 . Nonspecific binding of biotin and avidin was blocked by blocking solution (Protein Block Serum-Free; Dako, Carpinteria, CA, USA). The background staining was reduced with incubation with goat serum (1:20) for 60 minutes. Primary antibodies were placed on slides (1:100) and incubated for 1 hour at room temperature. Secondary antibodies conjugated with streptavidin/HRP (LSAB2; Dako) were used. The slides were washed and the antibody complex visualized by 3,3 ¶-diamino-benzidine (DAB; Dako). The nuclei were counterstained by Gill_s II hematoxylin.
Cases were considered positive if the staining was at least 2+ in the 1+-4+ scale, with more than 10% of the tumor cells staining above that of the background and negative control. Slides were scored as positive or negative by the authors (X. A. and M. J. A.), one of whom is a board certified pathologist.
Cell Culture and Western Blot
The HEI193 cell line was a gift from Dr. Lim (House Ear Institute, Los Angeles, CA, USA). VS cells were obtained from Copyright @ Otology & Neurotology, Inc. Unauthorized reproduction of this article is prohibited.
fresh VS tumor during planned surgical removal, after obtaining the necessary IRB (No. 07-0135). Cell lines were cultured in Dulbecco_s modified Eagle_s medium (DMEM), supplemented with 10% fetal bovine serum, 10,000 unit/ml penicillin G sodium, 10 mg/ml streptomycin sulfate (Invitrogen Co.), and L-glutamine (Invitrogen Co., Carlsbad, CA, USA) at 37-C in 5% CO 2 .
To determine the effect of Gleevec on HEI193, cells were treated with different concentrations of Gleevec for 24 hours, harvested, and evaluated by Western blot analysis. Cells were lysed with extraction buffer (1% [v/v] Triton X-100, 10 mmol/L Tris-HCl [pH, 7.4], 5 mmol/L ethylenediamine tetra-acetic acid, 50 mmol/L NaCl, 50 mmol/L NaF, 20 Kg/mL aprotinin, 1 mmol/L phenylmethylsulfonyl fluoride, and 2 mmol/L Na 3 VO 4 ) and subjected to 3 freeze/thaw cycles. The lysate was cleared by centrifugation at 20,000 Â g for 10 minutes, and the protein concentration was measured. A total protein concentration of 30 Kg was loaded per lane. Proteins were transferred onto nitrocellulose membranes and probed with the following primary antibodies: antiYc-kit (1:800), anti-PDGFR-Q (1:800), anti-phosphoc-kit (1:300), and anti-phospho-PDGFR-Q (1:300) (Cell Signaling Technology, Beverly, MA, USA), followed by incubation with the appropriate secondary antibodies. Membranes were then visualized with an enhanced chemiluminescence detection system (Pierce, Rockford, IL, USA). To demonstrate standardized loading, the membranes were probed with polyclonal antibody against A-actin ([1:1000]; Sigma-Aldrich, St. Louis, MO, USA).
Primary vestibular cells also were cultured from fresh tissue samples. After surgical removal, fresh tissues were immersed in ice-cold DMEM supplemented with gentamicin sulfate (Invitrogen Co.). Tissue samples were minced into 1-to 2-mm 3 explants and allowed to digest in DMEM containing 10% fetal bovine serum and 400 U/mL collagenase for 8 to 12 hours at 37-C into single cells. The tissue and cells were then collected, centrifuged, resuspended, and cultured in a cocktail consisting of 60% DMEM, 40% MCDB-210 (Sigma), 1% fetal bovine serum, 10 ng/ml recombinant human EGF (R&D Systems, Minneapolis, MN, USA), and 10 ng/ml recombinant PDGFR-BB (R&D Systems).
For protein analysis of PDGFR-A and c-Kit in fresh VS, a 25-mg piece of tissue was harvested and placed in cold lysis buffer for digestion. The sample was homogenized, and the final tissue in lysis buffer concentration was 5 mg/ml. The lysate was then centrifuged at 12,000 rpm. The pellet was discarded, and only the supernatant was retained for analysis. Western blot analysis was performed using anti-c-Kit (1:800), anti-PDGFR-Q (1:800) (Cell Signaling Technologies, Beverly, MA, USA) with MAPK (ERK1/2) as loading control.
Immunofluorescence Staining
Cells were plated on glass cover slides until they reached desired confluency. Cells were then fixed with 4% paraformaldehyde for 10 minutes. After washing with phosphatebuffered saline (PBS), the fixed cells were permeabilized with 0.2% Triton X-100. Cells were then incubated in the indicated primary antibodies, anti-c-kit (1:100) and anti-PDGFR-Q (1:100), for 1 hour at room temperature or overnight at 4-C. Primary antibodies were removed, and cells were washed with PBS and incubated in Alexa Fluor FITC-conjugated goat antimouse or goat antirabbit secondary antibodies (Molecular Probes; Invitrogen Co.) for 1 hour at room temperature. Slides were counterstained with 4_,6_-diamidino-2-phenylindole dihydrochloride (DAPI) (1.0 ng/mL) for 1 hour before final embedding. Fluorescent images were obtained using Leica DMIRE2 inverted fluorescence microscope. Computer program Simple PCI was used for image capture.
Cell Cycle Distribution
To determine the cell cycle distribution and levels of Gleevecinduced cell death, 1 Â 10 6 cells were harvested after the designated treatment and fixed in 50% cold ethanol overnight. The cells were then washed once with PBS and resuspended in a solution of PBS plus 0.1% Triton-X100, 2 mg/ml DNAase free RNaseA, and 0.02 mg/ml propidium iodide. Cells were analyzed by flow cytometry on a FACScan flow cytometer. Multicycle AV Cell Cycle software was used to calculate the fraction of cells in each phase of the cell cycle. Analyses were performed in triplicate, and indicated data represents the mean with standard deviation of the collected data.
Colony Formation Assay
Clonogenic survival assays were performed to assess the effectiveness of Gleevec in a VS cell line as well as in cells derived from a fresh VS tumor. The cells were plated in triplicate at 500 cells per 60 Â 15 mm culture plate and grown in DMEM supplemented with 10% FBS, L-glutamine, and antibiotics. Twenty-four hours after plating, the cells were incubated with a range of doses of Gleevec (0, 0.1, 0.5, 1, 5, 10, 20, and 40 KM). Colonies were fixed and stained with a crystal violet/formalin solution and counted after 7 to 10 days using the AlphaImager 2200 and 1220 software (Alpha Innotech Co., San Leandro, CA, USA). Colonies are defined as having 50 cells or more. 
RESULTS
Demographics and Patient Profile
A total of 34 patients were studied ( Table 1 ). The average age was 49.5 years (range, 25Y72 yr), with a 19:15 male/female ratio. All of the cases were sporadic VSs; there were no NF2 patients in the cohort. Twenty tumors were on the left side, and 15 were on the right. There were no cases of bilateral VSs in this cohort. The most common presenting symptom was hearing loss, followed by tinnitus and disequilibrium. Four patients had hyposthesias in the trigeminal area, and 2 patients had facial nerve paralysis. Audiometric data (pure-tone averages were calculated as the average of the thresholds at 0.5, 1, 2, and 3 kHz) available on 30 of these 31 patients demonstrated asymmetric sensorineural hearing loss by pure tone, and 18 of these 30 had profound hearing loss. The remaining 12 had audiometry between 35 and 60 dB. The results in all 20 patients who underwent tone decay tests and stapedial reflexes indicated that the pathology of the disease was retrocochlear. Imaging evaluation by MRI was performed in all patients, whereas 12 patients had both computed tomography and MRI. The size of the tumors is represented in Table 2 . Four patients underwent middle cranial fosa approach, 10 underwent retrosigmoid approach, and the remaining 20 underwent translabyrinthine approach.
Expression of the Tyrosine Kinases
PDGFR and c-Kit in VS Expression of PDGFR in the formalin-fixed tumor tissue was observed in 23 (67.5%) of the 34 samples. c-kit was expressed in 18 (52.9%) of the 34 samples (Table 2) . Representative staining of PDGFR-A and c-Kit in vestibular schwannoma are shown (Fig. 1) . All positive cases of PDGFR demonstrated cytoplasmic staining with membranous accentuation in the majority of the intensely staining cases. The average age among the PDGFR-positive (Fig. 2, A and C) . Treatment of HEI193 cells with Gleevec has no effect on total protein levels of these tyrosine kinases (Fig. 2A) . Furthermore, western analysis indicates that both 5 and 10 KM Gleevec can significantly downregulate levels of phospho-c-Kit and phospho-PDGFR-Q. Immunofluorescent staining reveals that PDGFR-Q is present and is localized primarily in the cytoplasm, whereas c-Kit is present in both the cytoplasm and nucleus, with intense expression in the nucleus (Fig. 2B) .
Gleevec Causes a G 1 Accumulation in HEI193
Incubation of HEI193 cells with Gleevec causes very little change in cell cycle distribution in the first 48 hours (Fig. 3 and Table 3 ). At 96 hours of exposure to Gleevec, there is a dose-dependent increase in G 1 from 61.6% to 70.7% and 74% at 5 and 10 KM of Gleevec, respectively ( Fig. 3 and Table 3 ). There also is a corresponding decrease of cells in S-phase from 26.6% to 17.7% and 13.2% with treatment with 5 and 10 KM of Gleevec, respectively. There is no significant change in the proportion of cells in G 2 in the presence or absence of Gleevec.
Gleevec Causes Inhibition of Cell Proliferation
In HEI193 and Primary VS Cells Colony formation assay was performed to assess the effect of Gleevec on long-term survival of HEI193 and primary VS cells. Figure 4 shows a dose-dependent decrease in the colony number of HEI193 cells (Fig. 4A) and a primary VS cell culture derived from a patient with sporadic VS (Fig. 4B ) with increasing concentration of Gleevec with an IC50 of approximately 7 KM for both cell cultures. Complete inhibition of colony formation was approached at the dose of 40 KM. Cell doubling time was roughly 24 hours. The mean T standard deviation of 3 separate repeated experiments is shown. Analysis of variance for both the HEI193 and the primary VS cell culture gives a p G 0.01.
DISCUSSION
The treatment for VS has improved significantly for the past several decades, resulting in lower mortality rates and reduced morbidity. Yet, even for a slow-growing tumor, surgical treatment still carries significant morbidity not only in terms of facial nerve paralysis or loss of hearing but also in postoperative headache that could severely affect the quality of life. Aside from this, in a subpopulation of patients who develop VS, surgery may not be an option, and therefore, alternative treatments are necessary. Furthermore, for recurrent VS or one in which a total excision is not feasible, medical therapy on its own or as an adjunct to surgery may have a role in managing this disease. Understanding the molecular biology of this disease is of critical importance for designing much needed alternative treatments. In this study, we have demonstrated that the tyrosine kinases c-Kit and PDGFR-Q that have been implicated in tumor development are expressed at high levels in a significant proportion of VS. To our knowledge, this is the first time that the expression of both these tyrosine kinases has been investigated in VS. c-Kit protein is a receptor type TK, structurally related to PDGFR. It plays an important role in the development of hematopoietic cells, melanocytes, and germ cells. It has been described to be expressed in several human solid tumors including small cell lung cancer, gastrointestinal stromal cell tumors, germ cell tumors, breast cancer, salivary gland tumors, and head and neck squamous cell carcinoma (29Y33). High levels of c-Kit have been reported in human schwann cells from patients with NF-1 (34) . c-Kit also has been implicated as one of the components leading to the neurofibrosarcomaderived Schwann cell hyperplasia observed in NF1 (35) .
Aberrant expression of PDGFR has been linked to various human tumors including small cell lung carcinoma (36) and ovarian carcinoma (37) . Constitutively active PDGFR tyrosine kinase is a common feature in idiopathic hypereosinophilic syndrome, eosinophiliaassociated chronic myeloid disorder, chronic myelomonocytic leukemia, systemic mast cell disease, atypical chronic myelogenous leukemia, and dermatofibrosarcoma protuberans (38) . The PDGFR family consists of the PDGFR> and A receptors that are stimulated by PDGF ligands. Both these receptors are known to be implicated in proliferation, intracellular organization, chemotaxis, apoptosis, and oncogenic transformation (38) . Gleevec has been shown to have remarkable activity in these hematologic malignancies and solid tumors, presumably, through its action on PDGFR.
As both PDGFR-Q and c-Kit are expressed at high levels in a significant proportion of the VS samples surveyed, we then proceeded to determine if Gleevec, a known inhibitor of these kinases, could inhibit phosphorylation of these 2 target proteins. Western blot analysis confirmed that Gleevec can downregulate phosphorylation of both PDGFR-Q and c-Kit in HEI-193 at clinically relevant doses. We then sought to determine whether Gleevec would have an effect on the proliferation of VS. Using an immortalized human VS cell line, HEI193, and a VS cell culture, both of which express PDGFR-Q and c-Kit, we demonstrate that Gleevec can inhibit their proliferation in a dose-dependent manner. Furthermore, we demonstrate that Gleevec can alter the cell cycle distribution and induce cell death in HEI193 cells. These experiments suggest that tyrosine kinases may have a role in the proliferation of VS cells and imply the potential for the use of small molecule tyrosine kinase inhibitors. Receptor and nonreceptor tyrosine kinases (TKs) have recently been the focus of a lot of attention as they have emerged as clinically useful drug targets for certain neoplasms. The small molecule inhibitors developed for these kinases have very specific targets and, thus, are not only very effective but also have minimal side effects and may be ideal for combined therapies. It also is important to note that Gleevec is a fairly nonspecific TK inhibitor and may act against other kinase targets in VS aside from PDGR and c-Kit. Future studies should investigate whether Gleevec_s ability to reduce cell growth also may be due to its interaction with other TKs implicated in Schwann cell neoplasia. As we learn more about the molecular biology of VS, even more specific and effective TK inhibitors can be developed that could revolutionize the treatment of this disease.
